Cargando…
CLK2 blockade modulates alternative splicing compromising MYC‐driven breast tumors
MYC oncogene overexpression/amplification is common in multiple human cancers, in which it regulates proliferation, apoptosis and cell metabolism, among other processes, and its expression associates with poor prognosis. Targeting MYC presents an exciting therapeutic possibility, but developing appr...
Autores principales: | Salvador, Fernando, Gomis, Roger R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991597/ https://www.ncbi.nlm.nih.gov/pubmed/29789342 http://dx.doi.org/10.15252/emmm.201809213 |
Ejemplares similares
-
Alternative splicing variability: exactly how similar are two identical cells?
por: Perriman, Rhonda J, et al.
Publicado: (2011) -
Stress-induced tRNA fragments take action in alternative splicing in Arabidopsis
por: Cao, Dechang
Publicado: (2023) -
Mutant Cullin causes cardiovascular compromise
por: Luft, Friedrich C
Publicado: (2015) -
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
por: Iwai, Kenichi, et al.
Publicado: (2018) -
Interferon blockade in lupus: effects on antiviral immunity
por: Steiger, Stefanie, et al.
Publicado: (2022)